Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial.

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A.

Prostate. 2015 Sep;75(13):1394-402. doi: 10.1002/pros.23020.

PMID:
26073992
2.

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial.

Veitonmäki T, Murtola TJ, Talala K, Taari K, Tammela T, Auvinen A.

PLoS One. 2016 Apr 21;11(4):e0153413. doi: 10.1371/journal.pone.0153413.

3.

Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level.

Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ.

Eur J Cancer. 2013 Mar;49(4):938-45. doi: 10.1016/j.ejca.2012.09.030.

PMID:
23079475
4.

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A.

Br J Cancer. 2014 Sep 23;111(7):1421-31. doi: 10.1038/bjc.2014.381.

5.

Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis.

Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, Gao Y, Qin X, Li S.

BMC Med. 2014 Mar 28;12:55. doi: 10.1186/1741-7015-12-55. Review.

6.

The use of aspirin and the risk of mortality in patients with prostate cancer.

Assayag J, Pollak MN, Azoulay L.

J Urol. 2015 Apr;193(4):1220-5. doi: 10.1016/j.juro.2014.11.018.

PMID:
25463991
7.

A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence.

Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ.

J Natl Cancer Inst. 2005 Jul 6;97(13):975-80.

PMID:
15998950
8.

The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy.

Bhindi B, Margel D, Hamilton RJ, Fernandes KA, Trottier G, Hersey KM, Finelli A, Trachtenberg J, Zlotta A, Kulkarni GS, Toi A, Evans A, van der Kwast TH, Fleshner NE.

Urology. 2014 Nov;84(5):1073-80. doi: 10.1016/j.urology.2014.05.071.

PMID:
25443907
9.

Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.

Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):390-6.

10.

5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A.

Int J Cancer. 2016 Jun 15;138(12):2820-8. doi: 10.1002/ijc.30017.

PMID:
26804670
11.

Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL; Urologic Diseases in America Project..

BJU Int. 2012 Oct;110(7):1050-9. doi: 10.1111/j.1464-410X.2011.10867.x.

12.

Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer.

Macfarlane TV, Murchie P, Watson MC.

Cancer Epidemiol. 2015 Dec;39(6):1015-22. doi: 10.1016/j.canep.2015.10.030.

PMID:
26590503
13.

Effect of aspirin and NSAIDs on risk and survival from colorectal cancer.

Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H, Dunlop MG.

Gut. 2010 Dec;59(12):1670-9. doi: 10.1136/gut.2009.203000. Review.

PMID:
20844293
14.

Use of aspirin postdiagnosis improves survival for colon cancer patients.

Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, van den Broek CB, Coebergh JW, Herings RM, van de Velde CJ, Fodde R, Liefers GJ.

Br J Cancer. 2012 Apr 24;106(9):1564-70. doi: 10.1038/bjc.2012.101.

15.

A cohort study investigating aspirin use and survival in men with prostate cancer.

Flahavan EM, Bennett K, Sharp L, Barron TI.

Ann Oncol. 2014 Jan;25(1):154-9. doi: 10.1093/annonc/mdt428.

PMID:
24356627
16.

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).

Murad AS, Down L, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC, Neal DE, Martin RM.

Int J Cancer. 2011 Mar 15;128(6):1442-8. doi: 10.1002/ijc.25465.

17.

Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort.

Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ.

Am J Gastroenterol. 2011 Jul;106(7):1340-50. doi: 10.1038/ajg.2011.38.

18.

Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink.

Wilson JC, O'Rorke MA, Cooper JA, Murray LJ, Hughes CM, Gormley GJ, Anderson LA.

Cancer Epidemiol. 2013 Dec;37(6):897-904. doi: 10.1016/j.canep.2013.08.010.

PMID:
24042024
19.

Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population.

Mahmud SM, Tanguay S, Bégin LR, Franco EL, Aprikian AG.

Eur J Cancer Prev. 2006 Apr;15(2):158-64.

PMID:
16523013
20.

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR.

Am J Epidemiol. 2012 Jul 15;176(2):156-63. doi: 10.1093/aje/kwr524.

Items per page

Supplemental Content

Support Center